Preservation and redirection of HPV16E7-specific T cell receptors for immunotherapy of cervical cancer

Scholten, Kirsten; Schreurs, Marco W. J.; Ruizendaal, Janneke J.; Kueter, Esther W. M.; Kramer, Duco; Veenbergen, Sharon; Meijer, Chris J.L.M.; Hooijberg, Erik

doi:10.1016/j.clim.2004.11.005

Cited by 42 publications

(39 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ϩ T-cell line carrying a TCR-responsive luciferase reporter construct (56). After transduction with the hPGK-1803 or SFFV-1803 lentiviral vector, greater than 95% of the Jurkat/MA cells expressed GFP and greater than 85% expressed a TCR that bound to the HLA-A*0201 SL9 peptide tetramer (Fig.…”

Section: Resultsmentioning

confidence: 99%

“…The Jurkat/MA cells have been stably transfected with an NFAT-luciferase reporter gene enabling them to be used to evaluate the functional activity of the expressed TCR as described previously (56). Briefly, T2 cells were preincubated with SL9 peptide or IV9 peptide at various concentrations ranging from 0.01 to 1 M for 2 h and washed, and the peptide-loaded T2 cells were added to cultures of Jurkat/MA cells transduced with the indicated lentiviral vector.…”

Section: Methodsmentioning

confidence: 99%

“…The 18030.D23.18 (1803) CTL clone is a human HLA-A*0201-restricted CD8 ϩ CTL that was cloned from an HIV-1-infected patient and is specific for the SL9 peptide (66 (56). Highly purified CD8 ϩ lymphocytes (Ͼ90% purity) were isolated from donor leukopacks from HIVnaive, HLA-A2-positive donors using MACS CD8 microbeads (Miltenyi Biotec, Germany) according to the manufacturer's instructions.…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Lentiviral Vectors Encoding Human Immunodeficiency Virus Type 1 (HIV-1)-Specific T-Cell Receptor Genes Efficiently Convert Peripheral Blood CD8 T Lymphocytes into Cytotoxic T Lymphocytes with Potent In Vitro and In Vivo HIV-1-Specific Inhibitory Activity

Joseph

Zheng²,

Follenzi³

et al. 2008

J Virol

Self Cite

View full text Add to dashboard Cite

The human immunodeficiency virus type 1 (HIV-1)-specific CD8 cytotoxic T-lymphocyte (CTL) response plays a critical role in controlling HIV-1 replication. Augmenting this response should enhance control of HIV-1 replication and stabilize or improve the clinical course of the disease. Although cytomegalovirus (CMV) or Epstein-Barr virus (EBV) infection in immunocompromised patients can be treated by adoptive transfer of ex vivo-expanded CMV-or EBV-specific CTLs, adoptive transfer of ex vivo-expanded, autologous HIV-1-specific CTLs had minimal effects on HIV-1 replication, likely a consequence of the inherently compromised qualitative function of HIV-1-specific CTLs derived from HIV-1-infected individuals. We hypothesized that this limitation could be circumvented by using as an alternative source of HIV-1-specific CTLs, autologous peripheral CD8 ؉ T lymphocytes whose antigen specificity is redirected by transduction with lentiviral vectors encoding HIV-1-specific T-cell receptor (TCR) ␣ and ␤ chains, an approach used successfully in cancer therapy. To efficiently convert peripheral CD8 lymphocytes into HIV-1-specific CTLs that potently suppress in vivo HIV-1 replication, we constructed lentiviral vectors encoding the HIV-1-specific TCR ␣ and TCR ␤ chains cloned from a CTL clone specific for an HIV Gag epitope, SL9, as a single transcript linked with a self-cleaving peptide. We demonstrated that transduction with this lentiviral vector efficiently converted primary human CD8 lymphocytes into HIV-1-specific CTLs with potent in vitro and in vivo HIV-1-specific activity. Using lentiviral vectors encoding an HIV-1-specific TCR to transform peripheral CD8 lymphocytes into HIV-1-specific CTLs with defined specificities represents a new immunotherapeutic approach to augment the HIV-1-specific immunity of infected patients.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Lentiviral Vectors Encoding Human Immunodeficiency Virus Type 1 (HIV-1)-Specific T-Cell Receptor Genes Efficiently Convert Peripheral Blood CD8 T Lymphocytes into Cytotoxic T Lymphocytes with Potent In Vitro and In Vivo HIV-1-Specific Inhibitory Activity

Joseph

Zheng²,

Follenzi³

et al. 2008

J Virol

Self Cite

View full text Add to dashboard Cite

show abstract

“…Though the safety and efficacy of this approach has been tested in other cancers such as melanoma, investigations into to TCR transfer and adoptive therapy for HPV-induced lesions is restricted by the limited availability of TCR with high affinity for HPV antigens. 109,110 However, efforts to isolate high affinity HPV-specific TCR are ongoing and once the relevant TCR are isolated, this approach will confer the appropriate tumor killing specificity and has the potential to generate a bank of TCR genes with specificity to various viral tumor antigens that may be selected for any patient with tumor cells expressing the appropriate antigen.…”

Section: T Cell Receptor Based Therapymentioning

confidence: 99%

Recent advances in strategies for immunotherapy of human papillomavirus‐induced lesions

Kanodia

Silva

Kast

2007

Intl Journal of Cancer

View full text Add to dashboard Cite

Human papillomavirus (HPV)-induced lesions are distinct in that they have targetable foreign antigens, the expression of which is necessary to maintain the cancerous phenotype. Hence, they pose as a very attractive target for ''proof of concept'' studies in the development of therapeutic vaccines. This review will focus on the most recent clinical trials for the immunotherapy of mucosal and cutaneous HPV-induced lesions as well as emerging therapeutic strategies that have been tested in preclinical models for HPVinduced lesions. Progress in peptide-based vaccines, DNA-based vaccines, viral/bacterial vector-based vaccines, immune response modifiers, photodynamic therapy and T cell receptor based therapy for HPV will be discussed. ' 2007 Wiley-Liss, Inc.Key words: human papillomavirus; immunotherapy; therapeutic vaccines; immunomodulation; animal models; clinical trialsThe human papillomaviruses (HPVs) are a family of sexually transmitted, double-stranded DNA viruses with over 100 different genotypes identified till date. HPV genotypes are divided into the low-risk and high-risk categories based on the spectrum of lesions they induce. Fifteen HPV types are classified as high-risk types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73 and 82); 3 are classified as probable high-risk types (26, 53 and 66) and 12 are classified as low-risk types (6,11,40,42,43,44,54,61,70,72, 81 and CP6108). 1 The low-risk types primarily induce benign genital condylomas and low-grade squamous intraepithelial lesions whereas the high-risk types are most frequently associated with the development of anogenital cancers and can be detected in 99% of cervical cancers, 2 with HPV16 found in about 50% of cases. 3 Infection by the low-risk types is not confined to the anogenital area and can cause other diseases such as recurrent respiratory papillomatosis. Similarly, infection by the high-risk types is also not confined to the anogenital area, since 18.3% of cancers of the oropharynx contain DNA from these types. 4 In the United States, an estimated 75% of the sexually active general population ages 15-49 years acquires at least one genital HPV type during their lifetime. 5 Though most individuals remain asymptomatic and spontaneously clear their infections, a small percentage of patients develop clinically or histologically recognizable lesions that develop into invasive cancer. The widespread use of cervical cytological screening using Papanicolaou (Pap) smear tests has reduced the mortality rate from cervical cancer in developed countries. However, in developing countries where screening programs are minimal, cervical cancer remains the second leading cause of cancer-related deaths among women. 6 Furthermore, Pap smear tests will not help identify HPV infection in males, where it can cause penile and anal cancers as well as cancers of the head and neck. Thus, it is essential to develop effective prophylactic and therapeutic strategies directed against HPV. Prophylactic vaccinesWhile therapeutic vaccines aim to develop a strong ...

show abstract

“…10,11 While genetic alteration of T cells with antigen-specific TCR genes confers the redirection of effector cells to the tumor, the recognition and the destruction of the latter still require the participation of MHC molecules. The alternative genetic approach to redirect T cells involves the introduction of a chimeric TCR into effector cells.…”

Section: Introductionmentioning

confidence: 99%

Genetically engineered T cells expressing a HER2-specific chimeric receptor mediate antigen-specific tumor regression

Yang

Urban

et al. 2008

Cancer Gene Ther

View full text Add to dashboard Cite

In this report, we developed a chimeric receptor (N29g chR) involving the single chain Fv (scFv) derived from N29 monoclonal antibody (mAb) specific for p185HER2 and characterized the therapeutic efficacy of primary T cells engineered to express N29g chR in two histologically distinct murine tumor models. Murine breast (MT901) and fibrosarcoma (MCA207) cancer cell lines were engineered to express human HER2 as targets. Administration of N29g chR-expressing T cells eliminated 3-day pulmonary micrometastases of MT901/HER2 and MCA207/HER2 but not parental tumor cells. A 5 to 8-fold increased dose of N29g T cells was required to mediate regression of advanced 8-day macrometastases. Exogenous administration of interleukin-2 (IL-2) after N29g T-cell transfer was dispensable for treatment of 3-day micrometastases, but was required for mediating regression of wellestablished 8-day macrometastases. Moreover, fractionated CD8 T cells expressing N29g chR suppressed HER2-positive tumor cell growth after adoptive transfer independent of CD4 þ cells. These data indicate that genetically modified T cells expressing a HER2-targeting chimeric receptor can mediate antigen-specific regression of preestablished metastatic cancers in a cell dose-dependent fashion. Systemic administration of IL-2 augments the therapeutic efficacy of these genetically engineered T cells in advanced diseases. These results are relevant to the implication of genetically redirected T cells in clinical cancer immunotherapy.

show abstract

Preservation and redirection of HPV16E7-specific T cell receptors for immunotherapy of cervical cancer

Cited by 42 publications

References 34 publications

Lentiviral Vectors Encoding Human Immunodeficiency Virus Type 1 (HIV-1)-Specific T-Cell Receptor Genes Efficiently Convert Peripheral Blood CD8 T Lymphocytes into Cytotoxic T Lymphocytes with Potent In Vitro and In Vivo HIV-1-Specific Inhibitory Activity

Lentiviral Vectors Encoding Human Immunodeficiency Virus Type 1 (HIV-1)-Specific T-Cell Receptor Genes Efficiently Convert Peripheral Blood CD8 T Lymphocytes into Cytotoxic T Lymphocytes with Potent In Vitro and In Vivo HIV-1-Specific Inhibitory Activity

Recent advances in strategies for immunotherapy of human papillomavirus‐induced lesions

Genetically engineered T cells expressing a HER2-specific chimeric receptor mediate antigen-specific tumor regression

Contact Info

Product

Resources

About